Corgenix Medical Corporation Signs Technology Transfer, Product Development Agreement With Mellitus LLC For Gestational Diabetes Test

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)

Under terms of the agreement, Corgenix will develop a test kit to measure GCD59 for Mellitus’ U.S. and European Union commercialization programs. Mellitus’ lead product candidate is a test for Gestational Diabetes Mellitus (GDM). GDM is a major cause of peri- and post-natal complications for mothers and babies.

Help employers find you! Check out all the jobs and post your resume.